Lundbeck acquires phase I-ready candidate from South Korean firm

Lundbeck has gained exclusive rights to biotherapy candidate APB-A1 from Aprilbio. The deal may cost up to USD 448m, and Lundbeck sees potential for the drug in several neurological indications.

Photo: Jens Dresling

Danish pharmaceutical giant Lundbeck has acquired exclusive rights to a biotherapy candidate for treating neurological diseases from Aprilbio, in a deal that may cost up to USD 448m.

This will hopefully liven up the company's pipeline, which has been sluggish of late.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs